Vermillion Releases Data from 494-Patient Study Supporting OVA1 | GenomeWeb

Vermillion this week released data from a new prospective, multi-center clinical study on its ovarian cancer diagnostic OVA1 that the company said "confirms and extends" previous studies supporting use of the test.

The 494-patient study, called OVA500, was conducted by Robert Bristow, director of gynecological oncology services at University of California, Irvine, Healthcare, and found that OVA1 identified ovarian cancer in women with an adnexal mass with sensitivity of 96 percent and specificity of 51 percent.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In PLOS this week: transcriptional and translational study of human cytomegalovirus interactions with host cells, spider web DNA study, and more.

The New York Stem Cell Foundation signs a lease for a new space.

Researchers gear up for an international meeting to discuss the ethics of gene editing.

In Nucleic Acids Research this week: personal genome approach to RNA-seq read alignment, hematopoietic Systems Biology Repository, and more.